New Trials in GI Cancers: Could Your Patient Benefit?
Maybe one of your patients can join a new clinical trial in noncolorectal gastrointestinal cancer?
Stay updated with breaking news from Ancer Liver . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Maybe one of your patients can join a new clinical trial in noncolorectal gastrointestinal cancer?
A single daily low dose of aspirin significantly reduced hepatic fat fraction and liver transaminase levels in a randomized trial in patients with metabolic-associated steatotic liver disease.
Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.
Omega-3 fatty acids downregulate expression of betacellulin in patients with NASH, providing a potential new avenue for prevention and treatment, a study has found.
A mathematical model forecasts a steady increase in liver disease burden, including a near doubling of liver cancers and a more than twofold increase in liver transplants.